Published in Drug Week, August 28th, 2009
Proceeds from the financing will primarily be used to expand Chimerix's clinical development program for its lead drug candidate, CMX001. CMX001 has shown activity in early clinical studies as a broad-spectrum antiviral drug, and is currently being evaluated for the treatment of cytomegalovirus (CMV) and BK virus in Phase II clinical trials. CMX001 is also...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2009-08-28)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.